Mammalian-enabled (MENA) protein enhances oncogenic potential and cancer stem cell-like phenotype in hepatocellular carcinoma cells

Kunpeng Hu1,*, Pinzhu Huang2,*, Hui Luo3, Zhicheng Yao1, Qingliang Wang1, Zhiyong Xiong1, Jizong Lin1, He Huang1, Shilei Xu1, Peng Zhang1 and Bo Liu1

1 Department of General Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
2 Department of Gastrointestinal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
3 Department of Operating Room, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Keywords
hepatic cancer stem cell; hepatic progenitor markers; hepatocellular carcinoma; mammalian-enabled; tumorigenicity

Correspondence
B. Liu, Department of General Surgery, The Third Affiliated Hospital, Sun Yat-sen University, NO. 2693, Kaichuang Road, Guangzhou 510630, China
Fax: +86 020 82179735
Tel: +86 18922103070
E-mail: liubojake@126.com

*Co-first authors
(Received 24 December 2016, revised 8 May 2017, accepted 23 May 2017)

doi:10.1002/2211-5463.12254

Liver cancer is one of the most common malignant tumors, with a worldwide incidence ranked No. 5 and a mortality rate ranked No. 3 in all malignant tumors [1]. In 2012, there are an estimated of 782 500 new cases and 745 500 deaths related to liver cancer worldwide [2]. In particular, China has a high incidence of liver cancer, accounting for about 50% of the global cases [2]. Hepatocellular carcinoma (HCC) is the most common subtype of liver cancer, accounting for about 85–90% of all primary liver cancers [3], with a poor prognosis due to the high rates of recurrence and metastasis [4].

Growing evidence suggests that cancer stem cells (CSCs) play an important role in the tumorigenicity of
a tumor [5]. According to the CSCs theory, CSCs are defined as a rare subset of cancerous cells within a tumor which are capable of self-renewal and regulating formation and development of tumor [6]. CSCs have been isolated in a variety of cancers, including HCC [7], breast cancer [8], pancreatic cancer [9], colon cancer [10], and melanoma [11]. Liver CSCs (LCSCs) have been shown to possess significant capacities of migration and invasion and resistant to radiation and chemotherapy, thus contributing to the tumor recurrence and metastasis [12]. Therefore, studying the molecular mechanisms underlying the role of LCSCs in recurrence and metastasis may be helpful to find new treatment strategies for liver cancer. Currently, several LCSC-related genes and biomarkers have been identified. It has been shown that human HCC cells with CD133 surface marker have the self-renewal capacity, and marked proliferation and colony formation potentials in vitro, as well as a remarkable tumorigenicity in vivo [13]. Cytokeratin-19 (CK19) is a LCSCs marker significantly associated with tumor size, reduced tumor differentiation, invasion, and metastasis [14,15]. In addition, the epithelial-to-mesenchymal transition (EMT)-related proteins were upregulated in CK19+ HCC cells [16]. Epithelial cell adhesion molecule (EpCAM) is a tumor-associated cell adhesion molecule with oncogenic potential in many endothelial-derived cancers [17]. Terris et al. [18] have demonstrated that EpCAM+ HCC cells have the characteristics of hepatic stem/progenitor cells and are able to form a highly invasive tumor in immunodeficient mice. Kimura et al. [19] showed that EpCAM+ HCC cells have a greater ability for colony formation in vitro and tumor formation in vivo as compared with EpCAM- HCC cells. Studies have shown that HCC cells with surface markers CD133, CD90, CD44, CK19, and EpCAM possess LCSC-like characteristics [20–22]. All these findings suggest that HCC cells expressing CSC biomarkers exhibit the characteristic of LCSCs and have a stronger tumorigenicity. However, the molecular mechanism about the regulation of expression of LCSC-related biomarkers remains not fully understood. Mammalian-enabled (MENA) is an actin-regulatory protein with a molecular weight of 80 kD and has the functions such as cell motility and adhesion [23]. MENA is undetectable in many normal tissues, but is highly expressed in gastric cancer, breast cancer, cervical cancer, colorectal cancer, pancreatic cancer, salivary gland cancer, and other adenocarcinomas; thus, it could be used as a tumor marker for these cancers [23]. In addition, researches on breast cancer have shown that expression of MENA is associated with tumor invasion and metastasis [24]. In the studies on hepatocellular carcinoma [25], MENA may be involved in the development and progression of tumors. Our previous study on 81 patients with HCC found that MENA is overexpressed in 40.74% paraffin-embedded HCC specimens. Compared to MENA-negative control, poor cellular differentiation, advanced tumor stage, and worse disease-free survival (DFS) have been found in MENA-positive group. Furthermore, multivariate Cox regression analysis shows that MENA overexpression is a risk factor for DFS (HR: 2.309, 95% CI: 1.104–4.828; P = 0.026) [26]. Recently, Lin et al. [25] demonstrated that knockdown of MENA reduced HCC cell migration and invasion in vitro, as well as their metastasis capacity in vivo. These results suggest an oncogenic potential for MENA.

Even though the oncogenic potential of MENA in HCC cells has been revealed, however, the underlying molecular mechanism remains to be investigated. MENA is an EMT-dependent alternatively spliced gene. The splice isoform of MENA with the exon 11a is a characteristic for epithelial cells and is not found in mesenchymal cells [27]. Meanwhile, the splice isoform of MENA has also been found to be expressed in primary tumor cells, but not in invasive tumor cells [28]. Although the detailed mechanism is still unknown, these findings suggest that MENA gene may play a role in the regulation of EMT. Multiple signaling pathways have been shown to be involved in the regulation of EMT and CSC transition [29,30], and there are many common regulation mechanisms between EMT and CSC. For instance, extracellular signal-regulated kinase (ERK) signaling has been shown to be involved in the regulation of both stemness [31] and EMT [32] in several cancers. Wnt/β-catenin pathway can promote the expression of surface markers of liver cancer and the promotion of liver CSC activation [33] and is involved in EMT of HCC [34]. Based on these observations, we hypothesized that MENA may play a role in the regulations of CSC and EMT in HCC cells. The purpose of this study was to investigate the oncogenic potential of MENA and its capacity to regulate CSC and EMT phenotypes in HCC cells. By using HCC tumor tissue samples and cancer cell lines, the above issues were investigated.

**Materials and methods**

**HCC samples**

A total of 81 tissue specimens of HCC were collected from primary HCC patients undergoing curative surgery in our center between March 2010 and July 2012 as previously described [26]. The median age of the patients was 49 years.
(range: 13–80 years); the median tumor size was 4.3 cm (range: 1.5–10 cm). All the patients were diagnosed with primary HCC; 69 (85%) patients were diagnosed with chronic viral hepatitis (HBV: 66 patients and HCV: three patients). This study was approved by the Institutional Review Board of the Third Affiliated Hospital of Sun Yat-sen University. Written informed consent was obtained from all the patients.

Cell culture

Hepatocarcinoma cell (HCC) lines QGY-7703 and PLC-8024 were obtained from the Institute of Virology, Chinese Academy of Medical Sciences (Beijing, China), while SMMC-7721, BEL-7402, HUH-7, MHCC-97L, and MHCC-97H were obtained from Liver Cancer Institute of Fudan University (Shanghai, China). All the hepatocarcinoma cell (HCC) lines were cultured by continuous passage in Dulbecco’s modified Eagle medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Gibco). Cells were maintained in a humidified incubator at 37 °C. All the hepatocarcinoma cell lines were cultured by continuous passage in Dulbecco’s modified Eagle medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Gibco). Cells were maintained in a humidified incubator at 37 °C in 5% CO2. RNA and protein were extracted from exponentially growing cells.

Generating stable MENA-overexpressing HCC cell lines

For stable overexpression of MENA, SMMC-7721 and QGY-7703 cells were infected with pLVX-IRES-Puro-MENA viral particles (Clontech; Mountain View, CA, USA) and selected by puromycin according to the manufacturer’s protocol. The established stable cell lines were designated as SMMC-7721-MENA and QGY-7703-MENA, respectively.

Western blot

Total proteins were extracted with RIPA lysis buffer and separated by SDS/PAGE and then transferred to the poly (vinylidene difluoride) membranes. The membranes were blocked with 5% skimmed milk and incubated with the appropriate antibody. The antigen–antibody complex on the membrane was detected with enhanced chemiluminescence reagents (Thermo Scientific, Rockford, IL, USA). The antibodies including ERK (Cat.#9926, Cell Signaling, Danvers, MA, USA) and p-ERK (Thr202/Tyr204, Cat.#9910, Cell signaling), E-cadherin (Cat.# sc-7470, Santa Cruz, Santa Cruz, CA, USA), vimentin (Cat.#sc-6260, Santa Cruz, Santa Cruz, CA, USA), β-catenin (Cat.# sc-6260, Santa Cruz), β-catenin (Cat.# 9562, Cell signaling), MENA (Cat.# 2075, Cell signaling), and α-tubulin (Cat.#ab15246, Abcam, Cambridge, MA, USA) were all used in this study.

In vitro cell migration assay

In vitro cell migration assays were performed in Transwell chambers (8 μm pore size; Costar). The Transwells were put into the 24-well plates. A total of 2 × 10⁵ cells were placed into the top chamber of each insert (BD Biosciences, Eugene, OR, USA) and incubated at 37 °C for 48 h. The migrated cells were fixed with 4% paraformaldehyde for 5 min, stained with 1% crystal violet for 30 s, and then quantified by counting cells at 20× magnification (five fields per chamber).

Colony formation assay and soft agar colony formation assay

For colony formation assay, QGY-7703-MENA and QGY-7703-Vector cells (200 cells/well) were trypsinized, plated on six-well plates, and then cultured in medium containing 10% FBS for 2 weeks. The colonies were fixed with 4% paraformaldehyde for 5 min and stained with 1% crystal violet for 30 s. To evaluate anchorage-independent cell growth, an assay of colony formation in soft agar was performed. A bottom layer was formed with 0.6% agar and Dulbecco’s modified Eagle’s medium (DMEM) plus 10% FBS in six-well plates. After the bottom layer solidified, 5000 cells per plate, 0.4% agar, and DMEM plus 10% FBS were added to the top layer. After 2 weeks of incubation, colonies were fixed with 4% paraformaldehyde for 5 min, stained with 1% crystal violet for 30 s, and counted for each plate.

RT-PCR

Total RNA was extracted from human HCC tissues and HCC cell line using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Total RNA extracts of CD133⁺ and CD133⁻ hepatoma cell lines (Huh7 and PLC-8024) were kindly provided by Guan XY (Sun Yat-sen University Cancer Center, China) [35]. First-strand cDNA was synthesized with 2 μg of total RNA using a First-Strand Synthesis System (Invitrogen) according to the manufacturer’s instructions. Real-time (RT) PCR was performed using a CFX96 Real-Time System (Bio-Rad, Hercules, CA, USA). 2 β SYBR Green Master mixture (Invitrogen) was used in a total volume of 10 μL. The PCR primer sequences were as follows: MENA: sense 5′-G TGCCATTCTCTAAAGGGTTGA-3′; antisense 5′-GCTCCCTACTCGCAG-3′; ABCG2: sense 5′-GGAGGAGAGGTAAGCATGTCCTACTCGCAG-3′; antisense 5′-CGCAAGCCCTCAT TTCAC-3′; Sox2F: sense 5′-GAAGGAGGTAAGCATGTCCTACTCGCAG-3′; antisense 5′-AGCATGTCCTACTCGCAG-3′. Written informed consent was obtained from all the patients.
ACCACAGGG-3'; β-catenin: sense 5'-ACAACGTGTGGTAAATCCA-3', antisense 5'-CGAGTCATTGCATACTGTC-3'; GAPDH: sense 5'-TGTGTGACATCAAGCCC-3' and antisense 5'-CTCCACGACGATCTCAGG-3', which was used as an internal control. All reactions were run in triplicate in three independent experiments.

**Chromatin immunoprecipitation (ChIP)**

Stable MENA-overexpressing HCC cells (QGY-7703-MENA) were trypsinized and treated with 1% formaldehyde for crosslinking, followed by sonication to lyse the cells and break down chromatin. The mixture of DNA and protein was immunoprecipitated with anti-β-catenin antibody. After extensive washing, elution, and de-crosslinking processes, the chromatin immunoprecipitation (ChIP)-DNA fragments were finally obtained. ChIP-DNA fragments were used as a template for PCR with specific primer pair for the promoter region of MENA gene (sense 5'-TA TATGCCTCCTCAAC-3', antisense 5'-GTTCCTGGCGTGGTTG-3').

**Statistical analysis**

Statistical analyses were performed using SPSS 17.0 for Windows (SPSS, IBM Corp., Armonk, NY, USA) and GraphPad Prism6 (GraphPad Software, La Jolla, CA, USA). Data were expressed as the mean ± standard error of the mean (SEM) from at least three independent experiments. Quantitative data between groups were compared using the Student’s t-test. A two-tailed P value of <0.05 was considered as statistical significance.

**Results**

**Generating MENA-overexpressing HCC cell lines**

Our previous work showed that overexpression of MENA is associated with poor cellular differentiation, advanced tumor stage, and worse DFS in HCC. To further investigate the oncogenic potential of MENA in vitro, we attempted to generate stable MENA-overexpressing HCC cell lines. MENA protein levels were screened in six HCC cell lines. As shown in Fig. 1A, Huh-7, PLC-8024, MHCC-97L, and MHCC-97H cells were positive for MENA protein, whereas SMMC-7721 and QGY-7703 cells were nearly negative for MENA. Therefore, two low MENA-expressing cell lines, SMMC-7721 and QGY-7703, were chosen to establish the stable MENA-overexpressing HCC cells (SMMC-7721 MENA and QGY-7703 MENA). The overexpression of MENA protein levels was confirmed by western blot in SMMC-7721-MENA (Fig. 1B) and QGY-7703-MENA (Fig. 1C).

**Overexpression of MENA enhanced tumorigenicity of HCC cells**

The proliferative and metastatic capacities of MENA-overexpressing HCC cells were determined to evaluate the oncogenic potential of MENA. As shown in Fig. 2, both colony formation (Fig. 2A, P < 0.001) and soft agar colony formation assay (Fig. 2B, P < 0.01) showed that QGY-7703-MENA cells can form significantly more colonies than the control cells. In addition, transwell cell migration assay showed that QGY-7703-MENA cells had a significantly higher migration ability as compared with the vector control cells (Fig. 2C, P < 0.01). These data suggested that overexpression of MENA enhanced tumorigenicity in HCC cell lines.

**Overexpression of MENA upregulated hepatic progenitor/stem cell markers and Wnt/β-catenin signaling markers in HCC cells**

As enhanced tumorigenicity is a characteristic of CSCs, next we investigated whether overexpression of MENA impacted on CSC-like characteristics of HCC cells. As shown in Fig. 3, overexpression of MENA dramatically upregulated the mRNA levels of hepatic progenitor cell (HPC) markers CK19 and EpCAM, stem cell markers Oct4 and Sox2, and Wnt signaling marker β-catenin in both stable MENA HCC cell lines as compared with their vector control counterparts.
However, the levels of CSC marker CD133 and stem cell marker ABCG2 did not change after overexpression of MENA. Real-time-PCR analysis found that MENA expression was only detected in total RNA extract of CD133\(^+\) Huh7 and PLC-8024 cells, but not in their CD133\(^-\) counterparts (Fig. 3C), indicating that only LCSCs express MENA. Taken together, these data suggested that MENA may play a role in CSC regulation of HCC cells.

High MENA protein was associated with high mRNA levels of MENA, CD133, CK19, and EpCAM in human HCC tissues

To further confirm whether MENA plays a role in CSC regulation of HCC cells, 81 human HCC tissues were divided into MENA-Low \((n = 48)\) and MENA-High groups \((n = 33)\) according to their expression level of MENA protein as previously described [26]. The mRNA levels of MENA, CSC marker CD133, HPC markers CK19 and EpCAM were compared between two groups. As expected, MENA mRNA level was significantly higher in MENA-High group than in MENA-Low group (Fig. 4A). In addition, MENA-High group had significantly higher mRNA levels of CD133 (Fig. 4B), CK19 (Fig. 4C), and EpCAM (Fig. 4D) as compared with MENA-Low group. These data indicated that high expression of MENA was associated with elevated CSC markers in HCC cells.

Overexpression of MENA promoted EMT, ERK phosphorylation, and \(\beta\)-catenin protein level

Finally, we attempted to investigate the molecular mechanism underlying MENA-mediated tumorigenicity enhancement in HCC cells. We examined the protein levels of two EMT biomarkers, E-cadherin and vimentin. As shown in Fig. 5A, overexpression of MENA simultaneously downregulated E-cadherin and upregulated vimentin in QGY-7703-MENA cells, suggesting that MENA promoted EMT. The data also showed that overexpression of MENA elevated protein...
level of p-ERK (Fig. 5A), suggesting that overexpression of MENA activates ERK signaling pathway.

Previous study has demonstrated that MENA is a transcriptional target of Wnt/β-catenin pathway [36]. To address whether β-catenin pathway is associated with MENA in HCC cells, we determined β-catenin protein level in QGY-7703-MENA cells. The data showed that MENA-overexpressing cells had a markedly increased protein level of β-catenin as compared with vector control cells (Fig. 5A). The result of ChIP also confirmed that β-catenin directly bound with the promoter region of MENA gene (Fig. 5B), demonstrating that MENA is a transcriptional target of β-catenin in HCC cells. These data implied that EMT, ERK, and β-catenin signaling pathways may be involved in the mechanism underlying MENA-mediated tumorigenicity enhancement in HCC cells.

Discussion
In this study, we investigated the oncogenic potential of MENA and its underlying mechanism in HCC cells. The data showed that overexpression of MENA significantly enhanced colony-forming and migration abilities in HCC cells. Overexpression of MENA in HCC cell lines also upregulated the HPC markers (CK19, EpCAM) and the stem cell markers (Oct4, Sox2). In addition, high MENA protein level was associated with elevated mRNA levels of the hepatic progenitor/stem cell markers CD133, CK19, and EpCAM in human HCC tissue samples. Furthermore, overexpression of MENA promoted EMT and ERK phosphorylation and level of β-catenin in HCC cells. These data suggested that MENA has the ability to enhance tumorigenicity and the expressions of CSC and EMT markers in HCC cells, which may be involved, at least partially, in the ERK and Wnt/β-catenin signaling pathways.

Our previous work showed that high expression of MENA in human HCC tissues is associated with poor cellular differentiation [26], implying that MENA may play a role in the dedifferentiation of HCC. The current study further demonstrated that HCC samples with elevated MENA protein displayed high levels of LCSC markers CD133, CK19, and EpCAM. In addition, MENA-overexpressing HCC cells showed enhanced hepatic progenitor/stem cell markers. CD133 is an important CSC surface marker in various tissues including HCC. Previous study reported that CD133+ cells accounted for 65% of Huh7 cells [37]. CD133+ cells had a greater colony-forming efficiency, higher proliferative capacity, and greater tumorigenicity [38]. In addition, CD133+ HCC cells have been shown to be more resistant to chemotherapy and radiotherapy through activation of the Akt/PKB and Bcl-2 survival pathways [37,39–41]. Chen et al. [42] showed that CD133+EpCAM+ Huh7 cells possessed elevated capacities for colony formation, differentiation, chemoresistance, and tumorigenicity in mice. Our data showed that MENA expression was detected only in CD133+ HCC cell lines Huh7 and PLC-8024 cells, but not in their CD133− counterparts. These results suggested that there is an association between CD133 and MENA. The phenomenon that overexpression of MENA in HCC cell lines resulted in unchanged level of CSC marker CD133 may indicate that MENA may be a downstream protein of CD133 so that overexpression of MENA had no effect on CD133 level. Further...
study is required to elucidate the relationship between CD133 and MENA in CSCs. These results also indicated that MENA may play a role in the regulation of CSC in HCC cells. It is worth to further investigate whether MENA regulates CD133+ LCSCs by establishing a MENA-overexpressing CD133+ HCC cell model.

In the current study, MENA-overexpressing HCC cells presented reduced E-cadherin and elevated vimentin proteins, indicating that the cells underwent EMT transformation. The EMT transition plays a crucial role in cancer invasion, metastasis, as well as for therapeutic resistance. CSCs have the capacity of self-renewal, migration, and invasion and are resistant to radiation and chemotherapy. Therefore, metastatic cancer cells may simultaneously possess the characteristics of both EMT and CSCs [43]. Accumulating evidences have identified the correlations between EMT and the CSC transformation in cancer cells [44,45]. Mani et al. [45] reported that immortalized human mammary epithelial cells undergoing EMT induce the expression of stem cell markers and form mammospheres, soft agar colonies, and tumors. In addition, several studies have suggested that HCC cells can acquire CSC-like characteristics through the EMT transition, exhibiting metastasis and therapeutic resistance [46–48]. Thus, both CSC and EMT are important for the invasion and metastasis of HCC. Our previous finding demonstrated that high expression of MENA in human HCC tissues is associated with advanced tumor stage [26]. In this study, MENA-

Fig. 4. High MENA protein was associated with high mRNA levels of MENA, CD133, CK19, and EpCAM in human HCC tissues. Eighty-one human HCC tissues were divided into MENA-Low (n = 48) and MENA-High groups (n = 33) according to their expression level of MENA protein. The mRNA levels of MENA (A), CSC marker CD133 (B), and HPC markers CK19 (C) and EpCAM (D) were determined by RT-PCR and compared between two groups (Student’s t-test).

Fig. 5. Overexpression of MENA promoted EMT, ERK phosphorylation and β-catenin protein level. (A) The protein levels of E-cadherin and vimentin, ERK, p-ERK, and β-catenin were determined by western blot and compared between QGY-7703-MENA and vector control cells. (B) ChIP was performed to analyze the β-catenin protein binding to the promoter region of MENA gene in HCC cells. Mouse IgG was used as a control immunoprecipitate antibody, while DNA sample that has not been immunoprecipitated was used as an input control. Panel a and panel b were two replicates of the experiment. The results showed that β-catenin directly bound with the promoter region of MENA gene.

study is required to elucidate the relationship between CD133 and MENA in CSCs. These results also indicated that MENA may play a role in the regulation of
MENA enhances CSC-like phenotype in HCCs

overexpressing HCC cells have elevated expression levels of both CSC and EMT markers and enhanced capacities of migration and colony formation, suggesting an oncogenic potential of MENA in HCC. In addition, our observations further supported the correlations between EMT and the CSC in HCC. To our best knowledge, our data report the effects of MENA on expressions of CSC and EMT markers in HCC cells for the first time, which also have not been described in any other cancers.

Both the molecular mechanisms of EMT and CSC are complicated, and there are many common regulation mechanisms between these two procedures. ERK and Wnt/β-catenin signaling pathways have been shown to be involved in the regulation of both stemness phenotypes [31,33] and EMT [32,34] in HCC. Our data showed that both the protein levels of p-ERK and β-catenin elevated in MENA-overexpressing HCC cells. In addition, the ChIP data showed that MENA is a transcriptional target of β-catenin in HCC cells. These findings suggested that MENA may regulate CSC features and EMT in HCC through Wnt/β-catenin and ERK pathways. Further study is needed to verify the detailed mechanism.

Several limitations should be mentioned in the current study. First, although our results found that overexpression of MENA elevated the levels of several LCSC biomarkers in HCC cells, we did not examine the effect of stable knockdown of MENA on the levels of LCSC biomarkers in high MENA-expressing cells. We also did not evaluate the effects of MENA overexpression on the other key features of CSC, such as capacity of self-renewal, drug resistance (i.e., sorafenib), and sphere formation to further confirm the CSC regulation function of MENA. In addition, we did not simultaneously implement the results for another MENA-overexpressing cell (SMMC-7721-MENA cell) in this study, and the immunofluorescence data of colocalization of MENA and stem cell markers (CK19 and CD133) in human HCC tissues are important to validate MENA as a stemness marker. Furthermore, in the following study, it is necessary to isolate MENA-+ LCSCs from fresh HCC surgical samples. These cells should be characterized for stemness features and proliferation ability using both in vitro and in vivo models. All these limitations should be addressed in the following study.

In summary, this study demonstrated that overexpression of MENA enhanced expression of CSC markers and EMT markers, as well as the tumorigenicity in HCC cells, which provide partial mechanisms for the oncogenic role of MENA in the metastasis and recurrence of HCC. Our findings may be helpful for the development of new therapeutic strategies for HCC.

Acknowledgements

This study was supported by the grants from Natural Science Foundation of Guangdong Province (2016A030313200), Science and Technology Project of Guangzhou City (201607010022), and Science and Technology Project of Guangdong Province (2014A020212715).

Author contributions

KH and BL planned experiments; PH performed experiments; HL, ZY, QW, and ZX analyzed data; JL, HH, SX, and PZ contributed reagents or other essential materials; KH and PH wrote the manuscript.

References

1 Siegel RL, Miller KD and Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66, 7–30.
2 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J and Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65, 87–108.
3 El-Serag HB and Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557–2576.
4 Saraswat VA, Pandey G and Shetty S (2014) Treatment algorithms for managing hepatocellular carcinoma. J Clin Exp Hepatol 4, S80–S89.
5 Bandhavkar S (2016) Cancer stem cells: a metastasizing menace! Cancer Med 5, 649–655.
6 Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, Visvader J, Weissman IL and Wahl GM (2006) Cancer stem cells - Perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66, 9339–9344.
7 Kwon T, Bak Y, Park YH, Jang GB, Nam JS, Yoo JE, Park YN, Bak IS, Kim JM, Yoon DY et al. (2016) Peroxiredoxin II is essential for maintaining stemness by redox regulation in liver cancer cells. Stem Cells 34, 1188–1197.
8 Coca C, Molgora S, Veronesi MC, Greco M, Bragato C, Moro M, Crosti M, Gray B, Milanesi L, Grieco V et al. (2016) FGF2 and EGF is required for self-renewal of canine normal and tumor breast stem/progenitor cells that have organoid formation potential. J Cell Biochem 118, 570–584.
9 Verma RK, Yu W, Shrivastava A, Shankar S and Srivastava RK (2016) α-Mangostin-encapsulated PLGA nanoparticles inhibit pancreatic carcinogenesis by targeting cancer stem cells in human, and transgenic...
MENA enhances CSC-like phenotype in HCCs

K. Hu et al.

(1) Wang J, Zhang B, Wu H, Cai J, Sui X, Wang Y, Li H, Qiu Y, Wang T, Chen Z et al. (2016) CD51 correlates with the TGF-beta pathway and is a functional marker for colorectal cancer stem cells. Oncogene 36, 1351–1363.

(2) Shidai C, Al-Rayyan N, Yaddanapudi K and Davis KR (2016) Lunasin is a novel therapeutic agent for targeting melanoma cancer stem cells. Oncotarget 7, 84128–84141.

(3) Sun JH, Luo Q, Liu LL and Song GB (2016) Liver cancer stem cell markers: progression and therapeutic implications. World J Gastroenterol 22, 3547–3557.

(4) Chiba T, Zheng YW, Kita K, Yokosuka O, Saisho H, Onodera M, Miyoshi H, Nakano M, Zen Y, Nakamura Y et al. (2007) Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 133, 937–950.

(5) Govaere O, Komuta M, Berkers J, Spee B, Janssen C, de Luca F, Katoonizadeh A, Wouters J, van Kempen LC, Durnez A, de Luca F, Katoonizadeh A, Wouters J, van Kempen LC, Durnez A et al. (2014) Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut 63, 647–685.

(6) Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, Columbano A and Thorgeirsson SS (2010) Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology 51, 1401–1409.

(7) Kim H, Choi GH, Na DC, Ahn EY, Kim G Il, Lee JE, Cho JY, Yoo JE, Choi JS and Park YN (2011) Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 54, 1707–1717.

(8) Trzpis M, McLaughlin PMJ, de Leij LMFH and Harmsen MC (2007) Epithelial cell adhesion molecule. Am J Pathol 171, 386–395.

(9) Terris B, Cavard C and Perret C (2010) EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 52, 280–281.

(10) Kimura O, Takahashi T, Ishii N, Inoue Y, Ueno Y, Kogure T, Fukushima K, Shiina M, Yamagiwa Y, Kondo Y et al. (2010) Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. Cancer Sci 101, 2145–2155.

(11) Liu LL, Fu D, Ma Y and Shen XZ (2011) The power and the promise of liver cancer stem cell markers. Stem Cells Dev 20, 2023–2030.

(12) Yamashita TT, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H et al. (2013) Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology 57, 1484–1497.

(13) Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D et al. (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120, 1444–1450.

(14) Gurzu S, Ciortea D, Ember I and Jungh I (2013) The possible role of mena protein and its splicing-derived variants in embryogenesis, carcinogenesis, and tumor invasion: a systematic review of the literature. Biomed Res Int 2013, 365192.

(15) Roussos ET, Wang Y, Wyckoff JB, Sellers RS, Wang W, Li J, Pollard JW, Gertler FB and Coneelis JS (2010) Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors. Breast Cancer Res 12, R101.

(16) Lin L, Yang XM, Li J, Zhang YL, Qin W and Zhang ZG (2014) Microfilament regulatory protein MENA increases activity of RhoA and promotes metastasis of hepatocellular carcinoma. Exp Cell Res 327, 113–122.

(17) Hu K, Wang J, Yao Z, Liu B, Lin Y, Liu L and Xu L (2014) Expression of cytoskeleton regulatory protein Mena in human hepatocellular carcinoma and its prognostic significance. Med Oncol 31, 939.

(18) Samatov TR, Tonevitsky AG and Schumacher U (2013) Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds. Mol Cancer 12, 107.

(19) Goswami S, Philippur U, Sun D, Patsialou A, Avraham J, Wang W, Di Modugno F, Nisticò P, Gertler FB and Coneelis JS (2009) Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clin Exp Metastasis 26, 153–159.

(20) Gonzalez DM and Medici D (2014) Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal 7, re8.

(21) Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX and Ivy SP (2015) Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol 12, 445–464.

(22) Huang B, Fu SJ, Fan WZ, Wang ZH, Chen ZB, Guo SJ, Chen JX and Qiu SP (2016) PKCδ inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P. Cancer Lett 376, 148–154.

(23) Fang D, Chen H, Zhu Y, Wang W, Teng Y, Ding HF, Jing Q, Su SB and Huang S (2017) Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways. Oncogene 36, 1546–1558.

(24) Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, Zhang SH, Huang DD, Tang L, Kong XN et al. (2008) Wnt/β-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 68, 4287–4295.
34 Ye Y, Long X, Zhang L, Chen J, Liu P, Li H, Wei F, Yu W, Ren X and Yu J (2016) NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma. *Oncotarget* 7, 70303–70322.

35 Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, Ng I, Man K, Wong N, To KF et al. (2010) miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. *Cell Stem Cell* 7, 694–707.

36 Najafov A, Seker T, Even I, Hoxhaj G, Selvi O, Ozel DE, Koman A and Birgil-Iyison N (2012) MENA is a transcriptional target of the Wnt/beta-catenin pathway. *PLoS ONE* 7, e37013.

37 Piao LS, Hur W, Kim TK, Hong SW, Kim SW, Choi JE, Sung PS, Song MJ, Lee BC, Hwang D et al. (2012) CD133(+) liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. *Cancer Lett* 315, 129–137.

38 Ma S, Chan K, Hu L, Lee TK, Wo JY, Ng IO, Zheng B and Guan X (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. *Gastroenterology* 132, 2542–2556.

39 Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J and Li J (2010) Cancer stem/progenitor cells are highly enriched in CD133 + CD44 + population in hepatocellular carcinoma. *Int J Cancer* 126, 2067–2078.

40 Ma S, Lee TK, Zheng BJ, Chan KW and Guan XY (2008) CD133 + HCC cancer stem cells confer chemotherapy resistance by preferential expression of the Akt/PKB survival pathway. *Oncogene* 27, 1749–1758.

41 Hagiwara S, Kudo M, Nagai T, Inoue T, Ueshima K, Nishida N, Watanabe T and Sakurai T (2012) Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. *Br J Cancer* 106, 1997–2003.

42 Chen Y, Yu D, Zhang H, He H, Zhang C, Zhao W and Shao RG (2012) CD133 + EpCAM+ phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 Cells. *Int J Biol Sci* 8, 992–1004.

43 Liu X and Fan D (2015) The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links. *Curr Pharm Des* 21, 1279–1291.

44 Scheel C and Weinberg RA (2012) Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. *Semin Cancer Biol* 22, 396–403.

45 Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 133, 704–715.

46 Kawai T, Yasuchika K, Ishii T, Katayama H, Yoshitoshi EY, Ogiso S, Kita S, Yasuda K, Fukumitsu K, Mizumoto M et al. (2015) Keratin 19, a cancer stem cell marker in human hepatocellular carcinoma. *Clin Cancer Res* 21, 3081–3091.

47 Yin X, Zhang BH, Zheng SS, Gao DM, Qiu SJ, Wu WZ and Ren ZG (2015) Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling. *J Hematol Oncol* 8, 23.

48 Liu YM, Li XF, Liu H and Wu XL (2015) Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells. *Oncol Rep* 34, 2977–2986.